KNSA vs PATH · P/E 53, rev $423.2M vs P/E 19, rev $1.61B
Kiniksa Pharmaceuticals Ltd (KNSA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported KNSA revenue for 2024-12-31 was $423.2M. Net income was -$43.2M. Revenue was up 56.6% from 2023-12-31 to 2024-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the KNSA and PATH stock pages for the full models.
Not investment advice.